Prescribing indicators at primary health care centers within the WHO African region: A systematic analysis (1995-2015) by Ofori-Asenso R et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Ofori-Asenso R, Brhlikova P, Pollock AM. Prescribing indicators at primary 
health care centers within the WHO African region: A systematic analysis 
(1995-2015). BMC Public Health 2016, 16, 174. 
 
 
Copyright: 
Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give appropriate credit to the original 
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were 
made. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, 
unless otherwise stated. 
DOI link to article: 
https://doi.org/10.1186/s12889-016-3428-8  
Date deposited:   
21/12/2017 
RESEARCH ARTICLE Open Access
Prescribing indicators at primary health
care centers within the WHO African
region: a systematic analysis (1995–2015)
Richard Ofori-Asenso1*, Petra Brhlikova2 and Allyson M. Pollock2
Abstract
Background: Rational medicine use is essential to optimize quality of healthcare delivery and resource utilization.
We aim to conduct a systematic review of changes in prescribing patterns in the WHO African region and
comparison with WHO indicators in two time periods 1995–2005 and 2006–2015.
Methods: Systematic searches were conducted in PubMed, Scopus, Web of science, Africa-Wide Nipad, Africa Journals
Online (AJOL), Google scholar and International Network for Rational Use of Drugs (INRUD) Bibliography databases to
identify primary studies reporting prescribing indicators at primary healthcare centres (PHCs) in Africa. This was
supplemented by a manual search of retrieved references. We assessed the quality of studies using a 14-point scoring
system modified from the Downs and Black checklist with inclusions of recommendations in the WHO guidelines.
Results: Forty-three studies conducted in 11 African countries were included in the overall analysis. These studies
presented prescribing indicators based on a total 141,323 patient encounters across 572 primary care facilities.
The results of prescribing indicators were determined as follows; average number of medicines prescribed per
patient encounter = 3.1 (IQR 2.3–4.8), percentage of medicines prescribed by generic name =68.0 % (IQR 55.4–80.3),
Percentage of encounters with antibiotic prescribed =46.8 % (IQR 33.7–62.8), percentage of encounters with injection
prescribed =25.0 % (IQR 18.7–39.5) and the percentage of medicines prescribed from essential medicines list =88.0 % (IQR
76.3–94.1). Prescribing indicators were generally worse in private compared with public facilities. Analysis of prescribing
across two time points 1995–2005 and 2006–2015 showed no consistent trends.
Conclusions: Prescribing indicators for the African region deviate significantly from the WHO reference targets. Increased
collaborative efforts are urgently needed to improve medicine prescribing practices in Africa with the aim of enhancing
the optimal utilization of scarce resources and averting negative health consequences.
Keywords: Prescribing indicators, Drug use indicators, Pharmacoepidemiology, Prescribing evaluation, Medicine utilization
studies, Systematic reviews, Africa
Background
According to the World Health Organization (WHO),
more than half of all medicines are inappropriately pre-
scribed, dispensed or sold with such practices deemed to
be most prevalent in healthcare settings in the developing
world where mechanisms for routine monitoring of medi-
cines use are still in early stages of development [1–4]. In
developing and low middle income countries, pharmaceu-
ticals account for a high proportion of household and
overall healthcare expenditure [5]. Improvement in the
way in which medicines are used is important in reducing
morbidity and mortality, building public confidence, re-
inforcing health system credibility as well as optimising
the utilisation of scarce resources [6–8]. The “wise list” in
Stockholm, Sweden for instance, is an example of an im-
provement in medicine use with an essential medicines list
(EML) with high adherence to just 200 medicines to im-
prove physician familiarity with quality medicines and re-
duce costs in a high income country that could provide
valuable lessons for developing countries seeking to
optimize resource utilization [9].
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Since the late 80's, the WHO together with the Inter-
national Network for Rational Use of Drugs (INRUD)
have been advocating proper documentation of medi-
cines use and have developed core drug use indicators in
three related areas of prescribing practices, patient care
and facility specific factors [10]. The drug use indicators
are regarded as objective measures that can be extended
to describe patterns of medicines usage in any health fa-
cility, country or an entire region.
The core drug use indicators include five prescribing
indicators which are meant to detail particular prescrib-
ing characteristics related to poly-pharmacy, antibiotic
use, injection use, generic prescribing and adherence to
the essential medicines list (EML) [10, 11]. Even though
an international standard of the prescribing indicators
has not been empirically determined, the WHO has rec-
ommended reference values for each of the indicators
(see Table 1) [12, 13]. In 1993, the WHO published the
guideline “How to investigate drug use at health facil-
ities: selected drug use indicators” aimed at outlining
methods for the collection and presentation of informa-
tion on medicines use in primary health care (PHC) set-
tings [10]. Subsequently, the WHO has been publishing
information on global medicines usage as part of its
World Medicines Situation reports [1, 4]. A more detailed
fact book focusing mainly on medicines use at PHCs in
developing and transitional countries was also published
in 2009 [14]. The broadest review on medicines usage was
published in 2013; this incorporates data from 900 studies
covering facilities at various level of care in 104 countries
between 1990 and 2009 [15]. For the African region, the
review reported the average number of medicines per pa-
tient encounter to be 2.6, percentage of encounters with
antibiotics prescribed as 45.9 %, percentage of encounters
resulting in prescription of injection as 28.4 %, percentage
of medicines prescribed from EML to be 89.0 % and per-
centage of medicines prescribed in generic name as 65.1 %
[15]. Despite not meeting the WHO targets, the estimates
show relatively frequent prescribing from EML and of
generic products. The high percentage of antibiotic and
injection prescriptions has been attributed to disease bur-
den, weak health systems and patients’ preferences. A
trend analysis showed ‘little progress over time’ [15].
The WHO African Region is one of the six regions of
the WHO and consists of 47 member states with over 927
million inhabitants in 2013 [16]. The region faces one of
the greatest disease burden compared to all other WHO
regions. In 2013, the life expectancy at birth in Africa was
58 years, the lowest among all the WHO regions and
10 years below that of Southeast Asia (68 years), the region
with the second lowest life expectancy [16]. According to
the 2013 Global burden of disease estimates, while their
relative burdens have seen some decline, communicable,
newborn, nutritional, and maternal causes such as diar-
rhoeal diseases, lower respiratory infections, and protein-
energy malnutrition still remain the top drivers of health
loss in most African countries [17]. Yet, many countries in
the region are also experiencing significant epidemiological
transition characterised by a growing burden of non-
communicable diseases (NCDs) thereby resulting in a
"double disease burden" [18]. For instance, a recent sys-
tematic review demonstrated consistent increase in preva-
lence of hypertension in Africa from 19.7 % in 1990 to
27.4 % in 2000 and 30.8 % in 2010 [19]. While the emer-
ging double disease burden presents unique public health
challenges and may call for greater intervention measures
resources for improving health delivery in Africa remain
scarce. In 2013, the region’s average total health expend-
iture per capita (PPP int. $) was 222, the lowest among all
WHO regions and extremely low when compared to Eur-
ope (2214) and Americas (3873) [16]. Additionally, there
are siginficant gaps in available health system structures
that hinder effective healthcare delivery. For instance, in
the period 2007–2013, the physician to population ratio
(per 10,000 population) in Africa was 2.7; this was far
lower than the global average of 13.9 [16]. According to
Motie [20], financial and human resource challenges
have hindered many healthcare systems within the African
region from evolving to meet the emerging healthcare de-
mands. The increasing emergence of non-communicable
diseases is likely to further exacerbate these trends.
Most health systems in Africa do not have established
mechanisms for routine system-wide medicine monitoring
and utilization. Moreover, reviews of specifically designed
studies are deemed to be out of date after 3 to 5 years or
even less (Whitlock et al.) [21]. This paper presents a sys-
tematic review to summarize available information on pre-
scribing indicators for the WHO African region over the
last two decades (1995–2015). Our aim was to critically
appraise the quality of studies on prescribing practices
in the Africa region and to compare the results of stud-
ies on prescribing indicators at PHCs in the African re-
gion against WHO recommended reference values. We
also wished to understand whether there are observable
differences in prescribing at private and public facilities
in the WHO African region. To this end, we defined
public to represent all fully government owned or
Table 1 WHO prescribing indicators and recommended
reference values [12, 13]
WHO prescribing indicator Reference value
Average number of medicines per encounter <2
Percentage of medicines prescribed by generic name 100 %
Percentage of encounters with an antibiotic prescribed <30 %
Percentage of encounters with an injection prescribed <20 %
Percentage of medicines prescribed from an essential
medicines list or formulary
100 %
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quasi-governmental facilities. Private was defined to
cover for-profit and mission health facilities.
Methods
WHO prescribing indicators
The prescribing indicators measure the performance of
healthcare providers in five key areas related to the appro-
priate use of medicines (Table 1) [10]. The derivation of
these indicators for any health facility (s) is based on an
analysis of patient clinical encounters. A patient encounter
is recognized to represent “the duration of interaction be-
tween patient and health provider. Ideally, this encounter
includes a number of components: history taking, diagno-
sis process: selection of non-pharmacological or pharma-
cological treatment, prescription (and perhaps dispensing)
of treatment; and explanations about treatment and its
adverse effects, follow-up, and prevention.” [22]. The en-
counters may be analyzed retrospectively using data from
medical history records or can be analyzed prospectively
as patients arrive during the period of data collection [10].
It is important to highlight that the determination of the
core prescribing indicators does not require information
on patients’ signs and symptoms as they provide general
prescribing tendencies (non-disease specific). The various
prescribing indicators are meant to elucidate peculiar pre-
scribing characteristics relating to polypharmacy, level of
antibiotic and injection use and adherence to guidelines
relating to generic and EML prescribing [23].
Studies retrieval process
We conducted a structured review of the literature in ac-
cordance with the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines [24].
Comprehensive searches were conducted in PubMed, Sco-
pus, Web of science, Africa-Wide Nipad, Africa Journals
Online (AJOL), Google scholar and INRUD Bibliography
databases. The main key words used were “primary health
care, primary health services, community health centres,
community-based healthcare, health facilities, primary
healthcare settings’ AND “prescribing indicators, prescrib-
ing patterns, drug use indicators, drug utilization patterns,
prescribing evaluation, prescribing statistics, rational pre-
scribing, rational use of medicines, health facility indica-
tors” AND “Africa, Sub-Saharan Africa, WHO African
Region”. The main limits used were ‘humans’ and ‘English’.
Additionally, we searched references of published reviews
and selected papers for additional publications.
Inclusion and exclusion of studies
We included only observational studies published in
English in peer-reviewed Journals between 1st January 1995
and 31st December 2015, which reported at least one
WHO/INRUD core prescribing indicator or where these in-
dicators were derivable from results/data presented. A study
must have specified the total number of patient encounters
involved for it to be accepted into the review. Furthermore,
to minimise potential bias, studies in which the patient en-
counters were derived through a random sampling tech-
nique were mainly included [25]. For studies with duplicate
publications, the version published first or one with
complete dataset was selected. In the case of interventional
studies, we included only pre (baseline) values. Although,
most hospital facilities provide secondary level care, in cer-
tain instances, outpatient departments provide primary care
services. Hence, where full description of this has been pro-
vided, studies conducted in such settings were included.
Critical appraisal of studies
Each study’s quality was assessed using a 14-point scoring
system modified from the Downs and Black checklist with
inclusions of recommendations in the WHO guidelines
(Table 2) [10, 26]. We awarded a one point value if study
satisfied each criteria. If study did not meet criteria, it was
awarded a zero. As studies may not assess all the five indi-
cators (e.g. a study may not measure antibiotic use), the
criteria were applied in relation to the indicator (s)
assessed. In view of this, the quality grading was expressed
as a percentage. Irrespective of the number of criteria ap-
plied, a study is considered as ‘high quality’ if it scores
≥70 % of the total tally scores based on the applicable cri-
teria. A score of 69–51 % was regarded as ‘moderate qual-
ity’ and a score of ≤50 % was graded as ‘low quality’.
Statistical analysis
Due to the wide heterogeneity of studies, a formal meta-
analysis was not conducted. We therefore adopted a more
Table 2 Studies’ quality appraisal checklist [10, 26]
1. Objective of the study clearly described
2. Study design or data collection methods clearly stated
3. Participants representative of a general patient population (Ideally
studies of prescribing indicators should involve a sample of general
illness encounters representing a mix of health problems)
4. Adequate sample size (WHO recommends a minimum of 600 encounters)
5. Whether type of facility was specified (i.e. public or private)
6. Whether the number of facilities involved was specified
7. Patient age/gender and other characteristics reported
8. Whether study described how medicines were counted (WHO
recommends that FDCs should be counted as one)
9. Whether study defined the medicines to be regarded as antibiotic
according to the WHO/INRUD classification if antibiotic indicator was
assessed (Only affects quality in terms of % antibiotics use)
10. Whether the reference essential medicines list (EML) used in the
study was specified. Researchers may utilize the WHO model EML,
facility EML or national EML as reference guide
11. Whether study specified the medicines regarded as injections.
Ideally, routine immunizations should not be counted as injections
(Only affects quality in terms of % of injections use).
12. Whether the statistical method employed in analyzing the results of
the study was appropriate and fully described
13. Whether the study described how missing data was handled and if
any confounders
14. Whether the study results were discussed appropriately. For instance,
if conclusion (s) were relevant to the findings
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descriptive approach as employed in previous reviews
[14, 15]. For each WHO/INRUD prescribing indicator,
we determined the median as well as the 25 and 75th
percentiles [14]. Mean values of prescribing indicators
across studies was not used as this would be unduly in-
fluenced by outliers [27]. To minimise the influence of
larger sample-sized studies, prescribing indicator values
were not weighted by sample size [14]. In this case, the
approach we adopted was to treat each study as a
single data point with equal weight, without regard
to sample size and variance. All computations were
done electronically using Microsoft Excel 2015® and
results of prescribing indicators were compared to
the WHO’s recommended reference values and with
previous reported values [12–15]. Statistical estimates
of the difference between the results of prescribing
indicators obtained for private and public PHCs as
well as between different publication periods was not
conducted since variance would have been greatly
underestimated in such circumstances [14]. Sub-
analysis was also conducted across different facility
ownerships (private vs public) as well as across the
studies publication periods 1995–2005 and 2006–
2015.
Results
Studies identification and retrieval
Figure 1 outlines the schematic flow of the studies' iden-
tification and inclusion processes. A total of 4208 articles
were identified by literature search. After the exclusion
of duplicates and irrelevant studies based on titles and
abstracts, 45 articles were retrieved for detailed full-text
analysis. Out of the 45 studies, 41 met the inclusion
criteria for addition to the review. Two (2) additional
studies were identified through the reference screening
bringing the total number of studies included in the re-
view to forty-three (43) [7, 8, 22, 28–67]. The 43 studies
included in this review (Table 3) collectively reported
WHO/INRUD prescribing indicators based on overall ana-
lysis of 141,323 patient encounters across 572 PHCs. The
PHCs included 359 (62.8 %) public and 213 (37.2 %) pri-
vate facilities. We were unable to separate ‘mission-based’
and ‘business/for-profit’ in the private facilities category as
studies gave a limited description of their activities. About
65.1 % (n = 28) of studies were published in the period
2006–2015 whereas 34.9 % (n = 15) were published in the
years 1995–2005. The 43 studies included in this review
were conducted in 11 countries representing 23.4 %
(11/47) of countries in the region under study. The 11
Fig. 1 Schematic flow diagram of studies' search and retrieval steps
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Table 3 Descriptive characteristics of included studies
No. Author Details Year of
Publication
Country Data collection
method
Data collection
duration
Mean age of
patients
Type of
facility (s)
No. of facilities Setting Prescriber type (s) No. of patient
encounters
1. Abdella and Wabe [28]. 2012 Ethiopia Retrospective 1 year n.s Public 1 Urban Health Officers 384
2. Adisa et al. [29]. 2015 Nigeria Prospective 3 months ≥15 Public 8 Urban n.s 400
3. Afriyie and Tetteh [30]. 2013 Ghana Retrospective 7 months n/s Public 1 Urban Medical assistants, Doctors 120
4. Afriyie et al. [31]. 2015 Ghana Prospective 6 months n/s Public 1 Urban Medical assistants, doctors 3127
5. Ahiabu et al. [32]. 2015 Ghana Retrospective 1 year n/s Private &
Public
4 (public = 1,
private = 3)
Urban Doctors, medical assistants 1600
6. Angamo et al. [33]. 2011 Ethiopia Prospective 6 weeks n/s Public 4 Urban n.s 3058
7. Babalola et al. [8]. 2011 Nigeria Retrospective 1 year 19.4 years Public 20 n/s Community health workers,
physicians, health assistants,
pharmacy technicians, nurses
and Pharmacist
560
8. Ball et al. [34] 2000 Zimbabwe Prospective n/s n/s Public 1 Urban Nurses 31
9. Bantie [35] 2014 Ethiopia Prospective n/s n/s Public 6 n/s n.s 600
10. Bexell et al. [36] 1996 Zambia Retrospective 3 months n/s Public 8 Urban Clinical officers 1167
11. Boonstra et al. [37] 2002 Botswana Prospective n/s 25.5 Public 30 Rural &
Urban
Registered nurse, Family
nurse practitioner
2994
12. Boonstra et al. [38] 2005 Botswana Prospective n.s <5 Public 30 Rural &
Urban
Nurses 255
13. Bosu and Ofori-Adjei [39] 2000 Ghana Retrospective 1 year 15 years Public 6 Rural Doctors and medical
assistants
585
14. Desta et al. [40] 1997 Ethiopia Prospective &
Retrospective
Prospective
1–2 days
Retrospective-1 year
n/s Public 18 n/s n.s 2340
15. Dippenar et al. [41] 2006 South Africa Prospective 2 month n/s Public 1 Urban Doctors, nurses 1000
16. Enato et al. [42] 2012 Nigeria Retrospective 6 months n/s Public 1 Rural Doctors, nurses 315
17. Enato et al. [43] 2013 Nigeria Retrospective 1 year n/s Public 3 Urban Community health officers 1440
18. Isah. [44] 2008 Nigeria Retrospective 1 year n/s Private 20 Rural n.s 2510
19. Kapp et al. [45] 2013 South Africa Retrospective 3 months 41.0 years Public 4 Urban n.s 400
20. Katende-Kyenda et al. [46] 2007 South Africa Retrospective 1 year n.s private 9 Urban n.s 83,655
21. Krause et al. [47] 1999 Burkina Faso Prospective 2 months n/s Public 9 Rural nurses 313
22. Massele and Nsimba. [48] 1997 Tanzania Prospective 20 days n/s Public &
Private
40 (public = 20,
private = 20)
Urban n.s 1200
23. Massele et al. [49] 2001 Tanzania Retrospective 14 months n/s Private 20 Rural &
Urban
Doctors 1200
24. Massele et al. [50] 2007 Tanzania Retrospective 1 year n/s Public &
Private
20 (public = 10,
Private = 10)
n/s n.s 2000
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Table 3 Descriptive characteristics of included studies (Continued)
25. Massele et al. [51] 2012 Tanzania Prospective 3 months n/s Public &
Private
20 (public = 10,
private = 10)
Urban Clinical officers, and other
paramedics
2000
26. Meyer et al. [52] 2001 South Africa Retrospective 1 month n/s Public 22 n/s Nurses 1287
27. Mohlala et al. [53] 2010 South Africa Prospective 5 months n/s Private 36 Rural &
Urban
Doctors 276
28. Nsimba et al. [54] 2004 Tanzania Retrospective 1 year n/s Private 10 n/s n.s 600
29. Nsimba [55] 2006 Tanzania Prospective n/s <5 years Public 10 n/s n.s 652
30. Odusanya and Oyediran [7] 2000 Nigeria Retrospective 6 months n/s Public 12 n/s Community health officers,
Public health nurses
650
31. Olayemi et al. [56] 2006 Nigeria Prospective &
Retrospective
Prospective-2–3days
Retrospective-n/s
n/s Public 20 Rural &
Urban
n.s 1560
32. Oyeyemi and Ogunleye [57] 2013 Nigeria Retrospective 1 year 34 years Public 4 Urban Medical officer, community
health officer, nurses and
community health extension
workers
600
33. Phillips-Howard et al. [58] 2003 Kenya Retrospective 1 year <5 Public 8 Rural n.s 9318
34. Risk et al. [59] 2013 Gambia Retrospective 1 year 1.71 Public 20 Rural &
Urban
n.s 2400
35. Savadogo et al. [60] 2014 Burkina Faso Prospective 1 month <5 Public 2 Urban n.s 376
36. Shiferaw et al. [61] 2010 Ethiopia Retrospective 1 year n/s Public 19 n/s n.s 731
37. Sisay and Mekonnen [62] 2012 Ethiopia Retrospective 2 years n.s Public 2 Urban n.s 424
38. Suleman et al. [63] 2013 Nigeria Retrospective 3 months n/s Public 10 n/s n.s 222
39. Tamuno [64] 2011 Nigeria Retrospective 1 year n.s Private 10 Urban n.s 998
40. Trap et al. [22] 2002 Zimbabwe Retrospective <6 months n/s Private 57 Urban Doctors 1699
41. Truter et al. [65] 2010 South Africa Retrospective 8 weeks n/s Public 1m Rural Supervised student trainees 4026
42. Tsega et al. [66] 2012 Ethiopia Retrospective 1 year 25 years Public &
Private
11 (public = 3,
private = 8)
Rural &
Urban
n.s 600
43. Uzochukwu et al. [67] 2002 Nigeria Retrospective n/s n/s Public 33 n/s n.s 1650
n.s not specified, m mobile clinic
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countries included Ghana (4), Nigeria (11), Tanzania
(6), Kenya (1), Gambia (1), Zambia (1), Zimbabwe (2),
South Africa (6), Ethiopia (7), Burkina Faso (2) and
Botswana (2).
Quality of studies
Overall, using the quality assessment criteria outlined,
51 % of studies were graded as of high quality whereas
42 % and 7 % were graded as of medium and low qual-
ity, respectively. The major factors that affected quality
grades of studies included smaller sample size, lack of
adherence to WHO recommendations (especially
counting and classification of medications) and poor
reporting of study information. Around one-third
(32.6 %) of studies included in the review involved patient
encounters <600 and were deemed to be small per recom-
mendations outlined in the WHO guidelines [10]. This is
an important consideration as studies with larger sample
size are more likely to present representative/generalizable
results.
The studies collected data either prospectively (using
current patients as they present for consultation) or
retrospectively (using past medical records). In 27 stud-
ies, data on prescribing were collected retrospectively, in
14 studies this was done prospectively while another two
studies used a mix approach of collecting prescribing in-
formation both prospectively and retrospectively. The
fact that majority of studies adopted a retrospective ap-
proach is quite understandable as such data are easier to
collect. Nonetheless, retrospective analysis introduces
some bias if certain information is excluded owing to
poor record keeping. In the study by Babalola et al. [8]
in Nigeria for instance, records of 40 patients were ex-
cluded from the analysis because they had incomplete
data while in the case of Massele et al. [50] in Tanzania,
the patient registers of three consecutive years were
abandoned for another register because they had incom-
plete data. It is possible that the excluded information
may have presented different prescribing characteristics
than those reported in the studies. Also most retrospect-
ive analyses rely on prescription sheets and hence may
exclude patients who are not prescribed medicines. This
is likely to lead to overestimation of variables such as
average number of medicines per patient, injection pre-
scribing rate and antibiotic prescribing rate although
EML and generic prescribing rates are unlikely to be
affected. While studies that adopted a prospective ap-
proach may minimize the loss of data and deal with other
limitations of retrospective assessments, they also intro-
duce an observer bias (Hawthorne effect) as it is difficult
to blind the health facility staff. In the Nsimba et al. [55]
study in Tanzania for instance, all health staff were briefed
on the study prior to prospective data collection. Pre-
scribers may modify their behaviour if they know they are
been investigated and as such, results derived this way
may also not be representative of typical prescribing be-
haviour [10]. In the two studies that adopted dual pro-
spective and retrospective analysis, no significant
difference in results were observed in the two approaches
thereby affirming to a large extent the validity of their
findings [40, 56].
It is recommended that prescribing indicators are ana-
lysed over an extended period (ideally ≥1 year) to
minimize the impact of seasonal variations in morbidity
patterns, peculiarities in staffing and inconsistencies in
medicines supply which can all impact on the patterns
of medicines prescribing [10, 39]. However, across stud-
ies reviewed, the period over which prescribing data
were collected varied widely from as short as 1 day to as
long as 24 months. Nineteen studies reported data col-
lection period less than 1 year and these are likely to be
prone to seasonal variations in prescribing and may not
necessarily represent usual trends.
Average number of medicines prescribed per patient
encounter
Information on the number of medicines prescribed per
patient encounter was obtained from 40 studies that in-
cluded a total 138,671 patient encounters. Among these
studies, the median number of medicines prescribed per
patient encounter was 3.1 (IQR 2.3–4.8) (Table 4). The
average number of medicines prescribed per patient en-
counter was higher for public 2.6 (IQR 2.2–4.7) than pri-
vate 2.5 (IQR 2.3–3.2) centres. The reported average
medicines prescribed per patient was higher for studies
published in the period 2006–2015 (3.5; IQR 2.2–5.6)
than the period 1995–2005 (2.4; IQR 2.3–4.0).
Percentage of medicines prescribed by generic name
Generic prescribing rate was reported in 33 studies that
involved a total of 121,797 patient encounters. Among
these studies, the generic prescribing rate was 68.0 %
(IQR 55.4–80.3). Public PHCs reported a higher percent-
age (68.9 %; IQR 57.6–84.5) of medicines prescribed
generically than private centres (61.3 %; IQR 47.7–75.7).
Generic prescribing rate for studies published in the
period 2006–2015 (70.4 %; IQR 60.7–81.1) was higher
than for studies published in the period 1995–2005
(64.2 %; IQR 51.9–77.9).
Percentage of encounters with antibiotic prescribed
Data on antibiotic prescribing rate was also retrieved
from 34 studies comprising of a total of 120,422 patient
encounters. The overall proportion of encounters result-
ing in the use of antibiotics was 46.8 % (IQR 33.7–62.8).
Public PHCs reported lower antibiotic prescribing rate
(45.0 %; IQR 30.13–60.2) compared to private facilities
(51.3 %; IQR 37.5–66.6). Higher antibiotic prescribing
Ofori-Asenso et al. BMC Public Health  (2016) 16:724 Page 7 of 14
rate was recorded among studies published in the period
2006–2015 (49.0 %; IQR 37.8–63.1) than for those pub-
lished in the period 1995–2005 (43.1 %, IQR 33.7–61.7).
Percentage of encounters with injection prescribed
Injection prescribing rate was retrieved from 32 studies
consisting of a total 40,096 patient encounters. The
overall proportion of encounters resulting in the pre-
scription of an injection was 25.0 % (IQR 18.7–39.5).
The proportion of encounters at public PHCs which re-
sulted in the prescription of an injection was determined
as 25.6 % (IQR 14.1–44.8) while that of private facilities
was 29.0 % (IQR 19.0–39.5). Injection prescribing rate
across studies published in the period 2006–2015
(25.0 %; IQR 17.1–41.4) was similar to studies published
in the period 1995–2005 (24.8 %; IQR 18.7–37.4).
Percentage of medicines prescribed from an essential
medicines list or formulary
Adherence to EML was determined using data from 27
studies in which a total of 101,077 medicines were pre-
scribed. The overall proportion of medicines prescribed
from an EML was estimated as 88.0 % (IQR 76.3–94.1).
Higher proportion of prescriptions from public centres
(89.9 %, IQR 82.9–95.6) adhered to the use of EML than
private centres (84.0 %; IQR 69.8–91.9). EML use rate
was higher among studies published in the period 2006–
2015 (88.9 %; IQR 70.8–94.0) than for the studies pub-
lished within 1995–2005 (87.1 %; IQR 84.9–92.0).
Discussion
Average number of medicines per patient encounter
Our review showed a high number of medicines (3.1) pre-
scribed per patient encounter. This value is higher than
that reported by the WHO factbook for the African region
(2.6) and that for the European (2.5), Southeast Asia (2.5)
and the Americas (1.8) regions [14]. The WHO analysis
was however based on a larger number of studies as the
review was not limited to studies published in peer-
reviewed journals, but included those reported in NGOs
and ministry of health reports as well as from other grey
literature. On the other hand, while the WHO factbook
and other reports have generally reported higher number
of medicines prescribed per patient in private compared
to public facilities we found the reverse with slightly
higher number of medicines per patient in public (2.6)
than private (2.5).
A generally high number of medicines prescribed per
patient exceeding WHO reference value may point to
polypharmacy as an increasing problem in Africa. Many
parts of the region are experiencing a changing epi-
demiological transition creating a double disease burden
of both communicable and NCDs [68] and there is evi-
dence that poly-pharmacy becomes more prominent
when health personnel need to treat multiple diseases
simultaneously [69, 70]. Additionally, demographic shifts
in most parts of Africa is resulting in an increasing eld-
erly population who are likely to suffer significant co-
morbidities and need for multiple medications [71, 72].
In countries like Ghana, Kenya, Nigeria and Tanzania
the population aged 60 and over is projected to increase
Table 4 Summary of prescribing indicators at PHCs within the WHO African region
Prescribing indicators
Average number of
medicines prescribed
per encountera
Percentage of
medicines prescribed
by generic name
Percentage of
encountersb with an
antibiotic prescribed
Percentage of
encountersb with an
injection prescribed
Percentage of medicines
prescribed from an
essential medicines list
WHO reference values
[12, 13]
<2 100 % <30 % <20 % 100 %
Facility type
All 3.1 (IQR 2.3–4.8) 68.0 % (IQR 55.4–80.3) 46.8 % (IQR 33.7–62.8) 25.0 % (IQR 18.7–39.5) 88.0 % (IQR 76.3–94.1)
n = 138,671 n = 121,797 n = 120,422 n = 40,096 n = 33,140
Publica 2.6 (IQR 2.2–4.7) 68.9 % (IQR 57.6–84.5) 45.0 % (IQR 30.1–60.2) 25.6 % (IQR 14.1–4.8) 89.9 % (82.9–95.6)
n = 44,596 n = 28,046 n = 26,071 n = 28,400 n = 23,044
Privatea 2.5 (IQR 2.3–3.2) 61.3 % (IQR 47.7–75.7) 51.3 % (IQR 37.5–66.6) 29.0 % (IQR 19.0–39.5) 84.0 % (IQR 69.8–91.9)
n = 92,475 n = 92,151 n = 92,751 n = 10,096 n = 8496
Studies publication period
1995–2005 2.4 (IQR 2.3–4.0) 64.2 % (IQR 51.9–77.9) 43.1 % (IQR 33.7–61.7) 25.0 % (IQR 17.1–41.4) 87.1 % (IQR 84.9–92.0)
n = 25,289 n = 13,949 n = 15,971 n = 14,549 n = 10,324
2006–2015 3.5 (IQR 2.2–5.6) 70.4 % (IQR 60.7-81.1) 49.0 % (IQR 37.8–63.1) 24.8 % (IQR 18.7–37.4) 88.9 % (IQR 70.8–94.0)
n = 113,382 n = 107,848 n = 104,451 n = 25,547 n = 22,816
IQR interquartile range, n total number of patient encounters used in analysis, aexcludes Ahiabu et al. [32] which did not provide individual results for public and
private facilities
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by around 147 %, 144 % and 80 %, respectively between
2005 and 2030 [73]. Such patterns may partly account
for the observed higher number of medicines prescribed
per patient in the period 2006–2015 (3.5) as compared
to the period 1995–2005 (2.4). Nonetheless, a number of
studies reviewed reported very high levels of symptom-
atic management of cases [44, 50], and this may have
also contributed to the overall high number of medicines
prescribed per patient.
Excessive use of multiple medicines per patient (poly-
pharmacy) is likely to result in increased risk of adverse
drug interactions, dispensing errors and decreased pa-
tients’ knowledge of the correct doses of medications. In
the study in Nigeria by Uzochukwu et al. [67], the per-
centage of patients remembering their dosing schedules
decreased significantly as the number of medicines in-
creased whereas Kapp et al. [45], reported a direct cor-
relation between the number of medicines prescribed
and the occurrence of adverse events in South Africa.
Increased risk of drug adverse effects as a result of
poly-pharmacy could create a cycle of health demands
and costs as new treatments may be required [74].
Percentage of medicines prescribed by generic name
Generics
The generic prescribing rate attained in this study (68.0 %)
was lower than that recommended by the WHO (100 %).
This result however portrays a better generic prescribing
rate than reported by the WHO factbook for the African
region (60 %) albeit based on smaller number of studies.
However, the results appear lower when compared to
values reported for the WHO’s Western Pacific region
(78 %), although higher than generic prescribing rates
reported for the Eastern Mediterranean (27.7 %) and
Southeast Asian regions (48.9 %) [14]. The lower generic
prescribing rate observed in private than public centres is
consistent with trends reported by the factbook as well as
other WHO reports [1, 14, 15].
The overall improved generic prescribing rate as docu-
mented by higher generic prescribing for the period
2006–2015 compared to the period 1995–2005 may be
due to the increasing availability of standard medicines
as generics. For instance, over 45 top brand medications
are expected to have patent expired between 2011 and
2020 and thus likely to make generic versions readily
available [75]. Once patency expires and availability/ac-
cessibility improves, lower cost becomes an incentive
that could drive generic prescription. As an example;
higher rates of generic prescribing [for proton pump in-
hibitors (PPIs) and statins] were seen in South Africa in
2010/2011 among patients enrolled into medical aid
schemes receiving discounted medications [76]. In
Netherlands, similar trends have been observed where
about threefold increase in statins utilization was
observed between 2000 and 2010 despite a 58 % de-
crease in reimbursed expenditure mainly as a result of
multiple supply and demand measures, including a prefer-
ential pricing policy [77]. Furthermore, in recent years,
considerable education and studies demonstrating no dif-
ference in outcomes between originators and generics
across a wide range of products and classes including anti-
psychotics, anti-infectives and cardiovascular medicines
have been undertaken and these may have contributed to
the increase in generic prescribing [78–81].
The lower generic prescribing rates observed for private
facilities may be due to the fact that prescribers in the pri-
vate sector may perceive generic medicines as not finan-
cially rewarding as patients typically purchase medicines
from same facilities and there may be a financial incentive
to prescribe most expensive products [22]. Additionally,
the more frequent prescribing of innovator (expensive)
brands in the private sector may be due to prescriber’s
quest to satisfy the expectations of their clients (often the
- well -to do) who may falsely perceive the issuance of ex-
pensive (innovator) medicines as constituting ‘quality
care’. Persistent prescription of branded (innovator) medi-
cines is likely to result in increased treatment costs. In a
study by Nwolisa et al. at outpatient centres in Nigeria,
the difference in cost between same drugs prescribed in
brand names as against generic names were between 41.7
% and 60 % [82]. Nicolosi and Gray investigated the cost
impact of generic and proprietary prescribing among
chronic disease patients in South Africa and their findings
indicated that of “all generic medicines identified 67.5 %
were more than 40 % cheaper, per defined daily dose
(DDD) per month, than the branded version” [83]. An ana-
lysis of facility-based medicines price data from 17 coun-
tries by Cameron and Laing [84], found that an average of
9–89 % could be saved by switching from originator brands
to lowest-price generic equivalents. To further improve
generic prescribing, diverse approaches may be adopted
including addressing fears related to generics, thorough
education of prescribers (beginning when they are in school
or training) or in some instance through the adoption of a
compulsory INN prescribing policy [85, 86].
Percentage of encounters with an antibiotic prescribed
The percentage of encounters with antibiotics prescribed
in this review was 46.8 % which exceeds the reference
value of <30 % recommended by the WHO [12]. The anti-
biotic use rate in this study is similar to that reported by
the WHO (47 %) [14]. However, it is lower when com-
pared to estimates provided for the Eastern Mediterranean
region (53.2 %) but higher than that of the Americas
(39.3 %) and European (33.5 %) regions [14]. A higher
value for antibiotic prescribing was reported for the pri-
vate facilities (51.3 %) than public facilities (45 %) which
does imply that antibiotic prescribing may be more of a
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problem in the private than public sector—an observation
consistent with WHO reported trends [1, 14].
The higher antibiotic prescribing rate reported for the
2006–2015 period than for the 1995–2005 period may
point to a non-improving or potentially worsening prob-
lem of antibiotic use in Africa. The overall high levels of
antibiotic prescribing may partly be accounted for by the
extensively documented high burden of infectious diseases
within the African region. For instance, in the studies by
Massele et al. [50] in Tanzania, Enato et al. [41] in Nigeria
and Bosu and Ofori-Adjei [39] in Ghana, 58 %, 38.3 % and
22 % of conditions presented at the PHCs, respectively
were attributable to infectious diseases (excluding mal-
aria). These high levels of reported infections are likely
to contribute to more antibiotic presciption. Addition-
ally, in many parts of Africa, HIV/AIDS remains en-
demic which although does not require the use of
antibiotics can increase the prevalence of opportunistic
bacterial infections necessitating the use of antibiotics
[53].
Regardless of the seemingly high levels of infection
rates, not all antibiotic prescribing and use reported may
be appropriate. In a number of studies, antibiotics were
reported as been prescribed to treat diseases like malaria,
diarrhoea and RTIs (mostly viral in origin) conditions
which do not usually require antibiotic use [40, 56, 59]. At
PHCs in many parts of Africa, microbiology laboratory fa-
cilities are often non-existent and as such prescribers may
rely mainly on their clinical judgment. While empirical
use of antibiotics based on clinical judgment other than la-
boratory confirmations is permitted in many instances
such as otitis, apparent pneumonia and cellulitis, it is well
recognized that consistent use of antimicrobials when in-
fection or diagnosis has not been established or fully con-
firmed can lead to overprescribing [87]. While it is
recommended good practice that medicines are written
for specified diagnosis, in one study conducted in Nigeria
by Isah [44], over 50 % of the patients’ folders reviewed
had no established diagnosis. In another study conducted
in Ethiopia by Desta et al. [40], the researchers reported
that any compliant presented by a patient was recorded as
final diagnosis. One study investigated prescribing pat-
terns across different health professionals and found
higher level of antibiotic prescribing more prevalent in
lower cadre staff like community nurses and health assis-
tants than in medical doctors and pharmacists [8]. How-
ever, across all the studies, higher antibiotic use were
generally reported for mix of health workers (physicians,
nurses, medical assistants etc.). Lack of in-service training
was recognised as contributing to poor prescribing prac-
tices as demonstrated by one study in Ghana, in which the
investigators reported that for the PHCs surveyed, none of
the prescribers had received an in-service training in the
preceding 5 years [39].
In addition to lack of adequate training, prevailing
socio-cultural factors and demand are known to influence
irrational antibiotics use [88]. These factors were reported
by some studies to have influenced prescribing behaviours
[40]. In private settings, prescribers are more likely to ad-
here to patient demand for antibiotics and injections for
fear of losing out on customers and this may underline
the higher antibiotic prescribing rate observed. Some
studies found a correlation between patient overload and
injection and antibiotic use [22, 64]. In many parts of
Africa there are widespread reports of acute shortage of
health staff, therefore in many instances, health personnel
may play dual role of prescriber and dispenser. Such oc-
currences can be a breeding ground for irrational pre-
scribing as no control mechanisms will be in place to
check wrong, incorrect or poor prescribing. Dispensing
prescribers may be more likely to prescribe irrationally in
the private-for-profit sector where there may be a financial
incentive for over-prescribing. For instance, Trap et al.
[22] found that PHC dispensing doctors were more likely
to prescribe antibiotics than non-dispensing doctors in
Zimbabwe. High patient load and inadequate prescriber
time can contribute to irrational prescribing as prescribers
may find it more convenient and time-saving to prescribe
an antibiotic rather than educate a patient that his condi-
tion does not require an antibiotic as it will require more
lengthy discussion [89]. In a study in Ghana by Polage et
al. [90], 98 % of physicians stated that they rarely order or
never order tests, because of time constraints.
Indiscriminate use of antibiotics backed by no diagnostic
certainty can contribute to the development of drug resist-
ance [87]. In one study included in this review, the re-
searchers carried out further antibiotic sensitivity testing.
Their findings indicated that, vaginal and endocervical iso-
lates were always resistant to the commonly used antibi-
otics such as ampicillin and tetracycline but almost always
sensitive to antibiotics like cefuroxime and gentamicin
which were less frequently prescribed at the facilities [39].
The development of antibiotic drug resistance can cause
significant morbidity and mortality as infectious disease
rates remain high in the African region. High use of anti-
biotics is also costly and the development of resistance
can further aggravate treatment cost by requiring the use
of more powerful and expensive antibiotics which are
likely to be unavailable in many parts of Africa. In the
Bosu and Ofori-Adjei study in Ghana, antibiotics alone
accounted for about 40 % of treatment cost in patients in
whom they were prescribed [39].
Percentage of encounters with an injection prescribed
The overall injection prescribing rate determined in this
study was 25.0 % which exceeds the reference value
(<20 %) recommended by the WHO [12]. The WHO fact
book reported an injection use rate of 27.5 % which is a
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bit higher than that attained in this study [14]. The result
also indicates a higher use of injectable medications when
compared to results reported for Eastern Mediterranean
(20.1 %), European (17.2 %) and West Pacific (23.2 %) re-
gions. In comparison, the study found higher use of injec-
tions at private facilities (29 %) than at public centres
(25.6 %) which is also in accord with global trends re-
ported by the WHO [1, 14]. The similar injection pre-
scribing rate in the periods 2006–2015 and 1995–2005
may highlight a non-changing injection use behaviours
among health personnel in Africa.
Widespread injection prescribing was reported across
all mix of health workers (doctors, nurses, medical assis-
tants etc.). Patient preference, socio-cultural beliefs have
been also noted to influence prescribing behaviours. In a
study by Massele and Mwaluko in Tanzania, it was re-
ported that some patients walked into the PHC facility
with their own supply of injectable medicines, syringes
and needles asking for them to be prescribed these med-
icines because they believed injections were more
powerful in restoring and maintaining health than other
formulations [91]. As indicated previously, patient influ-
ences are likely to be felt more in the private sector
where there may be a financial implication if prescribers
do not adhere to client demands. As the administration
of injections often requires supervision by skilled health
care providers, the frequency of prescription of injectable
medications is important [92]. Excessive and indiscriminate
use of injections can increase the risk of spreading blood-
borne diseases such as hepatitis B and even HIV/AIDS es-
pecially in a region where infections rates remain high.
Moreover, overuse of injections sets up a cycle of repeated
visits putting pressure on healthcare staff and driving costs.
Percentage of medicines prescribed from an essential
medicines list or formulary
The overall EML prescribing adherence of 88.0 % in this
study is comparable to the 87.8 % reported by the WHO
albeit lower than the optimal recommended value
(100 %) [13]. The EML prescribing rate presented in this
review is higher when compared to estimates reported
for other regions like the European (55.1 %), Americas
(71.4 %) and the South East Asia (81 %) regions [14].
The results obtained indicate that adherence to EML
when prescribing is better at public (93.5 %) that private
facilities (83.95 %), a pattern consistent with what has
been reported previously by the WHO [14, 15].
The general high EML prescribing rate may be due to
wider adoption of the use of EML in many countries as
well as expanding number of medicines on various
EMLs [93]. Regardless, the non-optimal use of EML as
reported in this study can be attributed to a myriad of
factors such as ineffective distribution of EML, inad-
equate sensitization among health workers and a general
lack of enforcement mechanisms. In separate studies by
Bosu and Ofori-Adjei [39] and Odusanya and Oyediran [7]
conducted in Ghana and Nigeria, respectively, all the facil-
ities studied lacked a copy of an EML. Moreover, some
studies reported that the main source of information for
prescribers were drug representatives [39, 49]. Such sources
have been documented to be problematic as drug compan-
ies may over-represent the efficacy of their medicines, dis-
credit the efficacy of competitor brands and likely to induce
prescribers to prescribe outside established guidelines [94,
95]. The lower EML adherence observed in private practice
may be due to the fact that in many countries in Africa, the
private sector is encouraged but not obliged to prescribe
from EML as may be the case for public centres [53].
Limitations
This systematic review has some limitations. Firstly, the
identified studies were concentrated in a few (11 out of
47) countries in the studied region. While a lack of re-
search into this area in parts of Africa may have contrib-
uted to this; it may have also been due to the inclusion of
only articles published in English and also the exclusion of
grey literature. Around one-third (32.6 %) of studies in-
cluded in the review involved patient encounters <600
and were deemed to be small per recommendations out-
lined in the WHO guidelines [10]. This review also took
the assumption that the African region is homogenous, al-
though, in reality, there may be differences in disease bur-
den, health system challenges, socio-cultural and political
climates across countries which all can affect how medi-
cines are used. Majority of the studies (74 %) also
collected data retrospectively. We consider that retro-
spective analysis may result in the overestimation of poly-
pharmacy (average number of medicines), antibiotic
utilization and injection use because patients who were
not given a prescription are likely to be excluded [25]. In
our analysis we stratified results by key sector (public and
private) but did not control for differences in prescriber
characteristics. Therefore, the apparent differences in the
prescribing indicators between the two sectors may be
due to multiple factors. We assessed prescribing indicators
at two time points and this is unlikely to reveal much
about prescribing trends. Importantly, this review reports
indicator-based studies which are unable to ascertain
whether the reported prescribed medicines were actually
taken by the patients involved. Indicator-based studies
while able to identify medicine use problem areas, do not
answer the question of rationality or appropriateness of
treatment which may require a different methodology and
analysis [23]. It is also important to reiterate that while the
prescribing indicator reference values are useful, these
have not been empirically determined and the extent to
which different factors influence them have not been thor-
oughly investigated [25].
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Conclusion
Our analysis reveals prescribing indicators at PHCs
within the WHO African region which deviate signifi-
cantly from proposed reference values. While our review
is based on limited studies, it does highlight that some
improvements in prescribing practices are needed. The
prescribing patterns observed are reflective of population
factors as well as varied health system challenges on the
African continent. Greater commitments from govern-
ments and all stakeholders are required to improve
medicine prescribing practices in the region. This is ne-
cessary not only to avert negative health consequences
but also to afford the optimal utilization of scarce
resources.
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